葛兰素史克-话题@MedSci

#葛兰素史克#

69篇内容 | 2634人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1315785, encodeId=026d1315e85e6, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=在需求激增的情况下，葛兰素史克和Vir提高了COVID-19抗体疗法Sotrovimab的产量, objectType=article, longId=294567, objectId=286329456e83, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=286329456e83, replyNumber=0, likeNumber=81, createdTime=2022-01-25, rootId=0, userName=sjq027, userId=d58a435, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=286329456e83, moduleTitle=在需求激增的情况下，葛兰素史克和Vir提高了COVID-19抗体疗法Sotrovimab的产量, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=286329456e83)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1315784, encodeId=e2161315e8468, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=葛兰素史克（GSK）寻求COVID-19单克隆抗体VIR-7831的紧急授权, objectType=article, longId=209106, objectId=7c5620910665, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c5620910665, replyNumber=0, likeNumber=77, createdTime=2021-03-29, rootId=0, userName=sjq027, userId=d58a435, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c5620910665, moduleTitle=葛兰素史克（GSK）寻求COVID-19单克隆抗体VIR-7831的紧急授权, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c5620910665)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1315783, encodeId=42471315e834b, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=葛兰素史克（GSK）和Medicago推出植物来源的COVID-19疫苗, objectType=article, longId=208619, objectId=60b7208619ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=60b7208619ce, replyNumber=0, likeNumber=81, createdTime=2021-03-20, rootId=0, userName=sjq027, userId=d58a435, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=60b7208619ce, moduleTitle=葛兰素史克（GSK）和Medicago推出植物来源的COVID-19疫苗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=60b7208619ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1315782, encodeId=668a1315e82fe, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=葛兰素史克中枢神经系统治疗药物利必通获批双相情感障碍新适应症, objectType=article, longId=208131, objectId=91b320813104, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=91b320813104, replyNumber=0, likeNumber=107, createdTime=2021-03-09, rootId=0, userName=sjq027, userId=d58a435, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=91b320813104, moduleTitle=葛兰素史克中枢神经系统治疗药物利必通获批双相情感障碍新适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=91b320813104)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1315781, encodeId=99721315e81dd, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=葛兰素史克中枢神经系统治疗药物利必通获批新适应症，为双相情感障碍患者带来一线用药新选择, objectType=article, longId=207762, objectId=4aba20e76244, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4aba20e76244, replyNumber=0, likeNumber=113, createdTime=2021-03-02, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4aba20e76244, moduleTitle=葛兰素史克中枢神经系统治疗药物利必通获批新适应症，为双相情感障碍患者带来一线用药新选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4aba20e76244)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1315780, encodeId=f3d31315e80ff, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=葛兰素史克（GSK）和CureVac制造针对新变体的COVID-19疫苗, objectType=article, longId=206778, objectId=9be9206e7855, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9be9206e7855, replyNumber=0, likeNumber=70, createdTime=2021-02-06, rootId=0, userName=sjq027, userId=d58a435, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9be9206e7855, moduleTitle=葛兰素史克（GSK）和CureVac制造针对新变体的COVID-19疫苗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9be9206e7855)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1315779, encodeId=c4921315e790f, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=葛兰素史克支付1.3亿英镑：加入开发基于mRNA的疫苗和抗体, objectType=article, longId=197877, objectId=3ae419e87787, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3ae419e87787, replyNumber=0, likeNumber=68, createdTime=2020-07-23, rootId=0, userName=sjq027, userId=d58a435, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3ae419e87787, moduleTitle=葛兰素史克支付1.3亿英镑：加入开发基于mRNA的疫苗和抗体, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3ae419e87787)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1315778, encodeId=823b1315e7819, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=欧洲药品管理局接受葛兰素史克的申请，寻求将Trelegy Ellipta三联吸入式疗法用于治疗哮喘, objectType=article, longId=189156, objectId=227218915615, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=227218915615, replyNumber=0, likeNumber=100, createdTime=2020-03-04, rootId=0, userName=sjq027, userId=d58a435, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=227218915615, moduleTitle=欧洲药品管理局接受葛兰素史克的申请，寻求将Trelegy Ellipta三联吸入式疗法用于治疗哮喘, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=227218915615)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1315777, encodeId=f31f1315e7787, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=FDA接受葛兰素史克的补充新药申请，将其PARP抑制剂Zejula用作对铂类化疗敏感、晚期卵巢癌患者的一线维持治疗, objectType=article, longId=188795, objectId=27b9188e9585, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=27b9188e9585, replyNumber=0, likeNumber=113, createdTime=2020-02-27, rootId=0, userName=sjq027, userId=d58a435, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=27b9188e9585, moduleTitle=FDA接受葛兰素史克的补充新药申请，将其PARP抑制剂Zejula用作对铂类化疗敏感、晚期卵巢癌患者的一线维持治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=27b9188e9585)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1315776, encodeId=33e81315e76cf, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=葛兰素史克和吉利德宣布加入抗击新型冠状病毒的全球阵营, objectType=article, longId=187380, objectId=07c218e3806a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=07c218e3806a, replyNumber=0, likeNumber=79, createdTime=2020-02-05, rootId=0, userName=sjq027, userId=d58a435, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=07c218e3806a, moduleTitle=葛兰素史克和吉利德宣布加入抗击新型冠状病毒的全球阵营, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=07c218e3806a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1315775, encodeId=aa551315e75bb, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=葛兰素史克、辉瑞和赛诺菲等制药商计划在美国提高200多种药品价格, objectType=article, longId=185776, objectId=b549185e76f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b549185e76f3, replyNumber=0, likeNumber=94, createdTime=2020-01-07, rootId=0, userName=sjq027, userId=d58a435, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b549185e76f3, moduleTitle=葛兰素史克、辉瑞和赛诺菲等制药商计划在美国提高200多种药品价格, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b549185e76f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1315774, encodeId=bb9e1315e7428, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=葛兰素史克宣布贝利尤单抗治疗狼疮性肾炎患者的III期临床试验取得整体阳性结果, objectType=article, longId=184997, objectId=556218499e7a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=556218499e7a, replyNumber=0, likeNumber=134, createdTime=2019-12-22, rootId=0, userName=sjq027, userId=d58a435, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=556218499e7a, moduleTitle=葛兰素史克宣布贝利尤单抗治疗狼疮性肾炎患者的III期临床试验取得整体阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=556218499e7a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1315773, encodeId=4d001315e73f5, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=葛兰素史克的贝利木单抗Benlysta治疗狼疮销量增加，2020年将向FDA申请用于治疗狼疮性肾炎, objectType=article, longId=184960, objectId=f8d018496047, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8d018496047, replyNumber=0, likeNumber=81, createdTime=2019-12-21, rootId=0, userName=sjq027, userId=d58a435, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8d018496047, moduleTitle=葛兰素史克的贝利木单抗Benlysta治疗狼疮销量增加，2020年将向FDA申请用于治疗狼疮性肾炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f8d018496047)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1315772, encodeId=fbaf1315e7209, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=葛兰素史克的靶向BCMA抗体偶联药物在多发性骨髓瘤研究中总缓解率达31％, objectType=article, longId=184903, objectId=60b518490392, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=60b518490392, replyNumber=0, likeNumber=67, createdTime=2019-12-19, rootId=0, userName=sjq027, userId=d58a435, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=60b518490392, moduleTitle=葛兰素史克的靶向BCMA抗体偶联药物在多发性骨髓瘤研究中总缓解率达31％, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=60b518490392)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1315771, encodeId=10b11315e7139, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=葛兰素史克的狼疮药物Benlysta在欧洲获得适应症扩容, objectType=article, longId=182190, objectId=e74d182190ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e74d182190ad, replyNumber=0, likeNumber=95, createdTime=2019-11-01, rootId=0, userName=sjq027, userId=d58a435, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e74d182190ad, moduleTitle=葛兰素史克的狼疮药物Benlysta在欧洲获得适应症扩容, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e74d182190ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1315770, encodeId=f3771315e7055, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=葛兰素史克（GlaxoSmithKline）将在所有市场上召回可能被污染Zantac（雷尼替丁）, objectType=article, longId=180872, objectId=46601808e2b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46601808e2b7, replyNumber=0, likeNumber=94, createdTime=2019-10-11, rootId=0, userName=sjq027, userId=d58a435, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46601808e2b7, moduleTitle=葛兰素史克（GlaxoSmithKline）将在所有市场上召回可能被污染Zantac（雷尼替丁）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=46601808e2b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1315769, encodeId=b5da1315e69cc, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=葛兰素史克正在日本寻求daprodustat治疗肾性贫血的批准, objectType=article, longId=178103, objectId=a6711e8103b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a6711e8103b1, replyNumber=0, likeNumber=86, createdTime=2019-08-23, rootId=0, userName=sjq027, userId=d58a435, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a6711e8103b1, moduleTitle=葛兰素史克正在日本寻求daprodustat治疗肾性贫血的批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a6711e8103b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1315768, encodeId=2b4c1315e68eb, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=葛兰素史克的双药片剂Dovato治疗艾滋病获FDA批准上市, objectType=article, longId=163973, objectId=7dc91639e359, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7dc91639e359, replyNumber=0, likeNumber=125, createdTime=2019-04-11, rootId=0, userName=sjq027, userId=d58a435, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7dc91639e359, moduleTitle=葛兰素史克的双药片剂Dovato治疗艾滋病获FDA批准上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7dc91639e359)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1315767, encodeId=25891315e677d, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=两项3期临床试验证实，葛兰素史克和强生的长效艾滋病疗法可以控制艾滋病毒, objectType=article, longId=161939, objectId=7e591619392f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e591619392f, replyNumber=0, likeNumber=64, createdTime=2019-03-10, rootId=0, userName=sjq027, userId=d58a435, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e591619392f, moduleTitle=两项3期临床试验证实，葛兰素史克和强生的长效艾滋病疗法可以控制艾滋病毒, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e591619392f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1315766, encodeId=c68a1315e666b, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=葛兰素史克GSK以51亿美元收购了生物制药公司Tesaro, objectType=article, longId=159123, objectId=a39715912350, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a39715912350, replyNumber=0, likeNumber=104, createdTime=2019-01-30, rootId=0, userName=sjq027, userId=d58a435, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a39715912350, moduleTitle=葛兰素史克GSK以51亿美元收购了生物制药公司Tesaro, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a39715912350)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

葛兰素史克

2020-05-29

sjq027 (审核中...)

前往app查看评论内容

#葛兰素史克#

在需求激增的情况下，葛兰素史克和Vir提高了COVID-19抗体疗法Sotrovimab的产量

2022-01-25

sjq027 (审核中...)

前往app查看评论内容

#葛兰素史克#

葛兰素史克（GSK）寻求COVID-19单克隆抗体VIR-7831的紧急授权

2021-03-29

sjq027 (审核中...)

前往app查看评论内容

#葛兰素史克#

葛兰素史克（GSK）和Medicago推出植物来源的COVID-19疫苗

2021-03-20

sjq027 (审核中...)

前往app查看评论内容

#葛兰素史克#

葛兰素史克中枢神经系统治疗药物利必通获批双相情感障碍新适应症

2021-03-09

仁者大医 (审核中...)

前往app查看评论内容

#葛兰素史克#

葛兰素史克中枢神经系统治疗药物利必通获批新适应症，为双相情感障碍患者带来一线用药新选择

2021-03-02

sjq027 (审核中...)

前往app查看评论内容

#葛兰素史克#

葛兰素史克（GSK）和CureVac制造针对新变体的COVID-19疫苗

2021-02-06

sjq027 (审核中...)

前往app查看评论内容

#葛兰素史克#

葛兰素史克支付1.3亿英镑：加入开发基于mRNA的疫苗和抗体

2020-07-23

sjq027 (审核中...)

前往app查看评论内容

#葛兰素史克#

欧洲药品管理局接受葛兰素史克的申请，寻求将Trelegy Ellipta三联吸入式疗法用于治疗哮喘

2020-03-04

sjq027 (审核中...)

前往app查看评论内容

#葛兰素史克#

FDA接受葛兰素史克的补充新药申请，将其PARP抑制剂Zejula用作对铂类化疗敏感、晚期卵巢癌患者的一线维持治疗

2020-02-27

sjq027 (审核中...)

前往app查看评论内容

#葛兰素史克#

葛兰素史克和吉利德宣布加入抗击新型冠状病毒的全球阵营

2020-02-05

sjq027 (审核中...)

前往app查看评论内容

#葛兰素史克#

葛兰素史克、辉瑞和赛诺菲等制药商计划在美国提高200多种药品价格

2020-01-07

sjq027 (审核中...)

前往app查看评论内容

#葛兰素史克#

葛兰素史克宣布贝利尤单抗治疗狼疮性肾炎患者的III期临床试验取得整体阳性结果

2019-12-22

sjq027 (审核中...)

前往app查看评论内容

#葛兰素史克#

葛兰素史克的贝利木单抗Benlysta治疗狼疮销量增加，2020年将向FDA申请用于治疗狼疮性肾炎

2019-12-21

sjq027 (审核中...)

前往app查看评论内容

#葛兰素史克#

葛兰素史克的靶向BCMA抗体偶联药物在多发性骨髓瘤研究中总缓解率达31％

2019-12-19

sjq027 (审核中...)

前往app查看评论内容

#葛兰素史克#

葛兰素史克的狼疮药物Benlysta在欧洲获得适应症扩容

2019-11-01

sjq027 (审核中...)

前往app查看评论内容

#葛兰素史克#

葛兰素史克（GlaxoSmithKline）将在所有市场上召回可能被污染Zantac（雷尼替丁）

2019-10-11

sjq027 (审核中...)

前往app查看评论内容

#葛兰素史克#

葛兰素史克正在日本寻求daprodustat治疗肾性贫血的批准

2019-08-23

sjq027 (审核中...)

前往app查看评论内容

#葛兰素史克#

葛兰素史克的双药片剂Dovato治疗艾滋病获FDA批准上市

2019-04-11

sjq027 (审核中...)

前往app查看评论内容

#葛兰素史克#

两项3期临床试验证实，葛兰素史克和强生的长效艾滋病疗法可以控制艾滋病毒

2019-03-10

sjq027 (审核中...)

前往app查看评论内容

#葛兰素史克#

葛兰素史克GSK以51亿美元收购了生物制药公司Tesaro

2019-01-30

科室
- - 订阅+
  - 更多科室
工具
服务